Ahmet İlHan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmet İlHan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ali Adili
Department of Oncology, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Ahmad Saburi
Department of Biology, Faculty of Basic Sciences, Gonbad Kavous University, Gonbad Kavous, Iran
1 shared publication - Amirhossein Fakhre Yaseri
School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran
1 shared publication - Burhan Abdullah Zaman
Basic Sciences Department, College of Pharmacy University of Duhok Duhok Kurdistan Region Iraq
1 shared publication - Gulinnaz Ercan
Department of Medical Biochemistry, Faculty of Medicine, Ege University, İzmir, Turkey
1 shared publication - Hasti Etemadi
Department of Biotechnology, Rajiv Gandhi Institute of IT and Biotechnology, Bharati Vidyapeeth University, Pune, India
1 shared publication
Latest Publications
- Open Access
- 7 July 2022
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 15 (1) , 1-14
A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview
Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics.
- 7 July 2022
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 15 (1) , 1-14
Open AccessA comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview
Ovarian cancer (OC), a frequent malignant tumor that affects women, is one of the leading causes of cancer-related death in this group of individuals. For the treatment of ovarian cancer, systemic chemotherapy with platinum-based drugs or taxanes is the first-line option. However, drug resistance developed over time during chemotherapy medications worsens the situation. Since uncertainty exists for the mechanism of chemotherapy resistance in ovarian cancer, there is a need to investigate and overcome this problem. miRNAs are engaged in various signaling pathways that contribute to the chemotherapeutic resistance of ovarian cancer. In the current study, we have tried to shed light on the mechanisms by which microRNAs contribute to the drug resistance of ovarian cancer and the use of some microRNAs to combat this chemoresistance, leading to the worse outcome of ovarian cancer patients treated with systemic chemotherapeutics.
- Open Access
- 4 May 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-37
CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
The progress of genetic engineering in the 1970s brought about a paradigm shift in genome editing technology. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) system is a flexible means to target and modify particular DNA sequences in the genome. Several applications of CRISPR/Cas9 are presently being studied in cancer biology and oncology to provide vigorous site-specific gene editing to enhance its biological and clinical uses. CRISPR's flexibility and ease of use have enabled the prompt achievement of almost any preferred alteration with greater efficiency and lower cost than preceding modalities. Also, CRISPR/Cas9 technology has recently been applied to improve the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies and defeat tumor cell resistance to conventional treatments such as chemotherapy and radiotherapy. The current review summarizes the application of CRISPR/Cas9 in cancer therapy. We also discuss the present obstacles and contemplate future possibilities in this context.
- 4 May 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-37
Open AccessCRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
The progress of genetic engineering in the 1970s brought about a paradigm shift in genome editing technology. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) system is a flexible means to target and modify particular DNA sequences in the genome. Several applications of CRISPR/Cas9 are presently being studied in cancer biology and oncology to provide vigorous site-specific gene editing to enhance its biological and clinical uses. CRISPR's flexibility and ease of use have enabled the prompt achievement of almost any preferred alteration with greater efficiency and lower cost than preceding modalities. Also, CRISPR/Cas9 technology has recently been applied to improve the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies and defeat tumor cell resistance to conventional treatments such as chemotherapy and radiotherapy. The current review summarizes the application of CRISPR/Cas9 in cancer therapy. We also discuss the present obstacles and contemplate future possibilities in this context.